Herceptin Sales Data
| Rank 24 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: May 2013 (updated quarterly).
The following data shows Herceptin U.S. retail sales in Q1 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q1 2013 | 24 | $471,387 | 1.43% | 167 | 1.83% |
| Q4 2012 | 24 ( 2) |
$464,737 | 3.22% | 164 | 1.23% |
| Q3 2012 | 26 (4) |
$450,251 | -0.84% | 162 | -0.61% |
| Q2 2012 | 30 (3) |
$454,063 | 6.67% | 163 | 5.16% |
| Q1 2012 | 33 | $425,687 | -0.06% | 155 |  |
| Q4 2011 | 33 ( 2) |
$425,931 | 7.61% | 155 | 4.73% |
| Q3 2011 | 31 (1) |
$395,804 | -0.64% | 148 | -0.67% |
| Q2 2011 | 32 (4) |
$398,348 | 3.62% | 149 | 1.36% |
| Q1 2011 | 36 | $384,428 | |
147 | |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
See Also
Related News
| Date | Article |
|---|---|
| October 5, 2011 | Drug Combo Might Fight Aggressive Breast Cancer More Safely |
| August 10, 2011 | Breast Cancer Drug Raises Risk of Heart Problems in Older Women: Study |
| June 14, 2011 | FDA Approves Test That Spots HER2-Positive Breast Cancers |
| June 14, 2011 | New Test Helps Evaluate Breast Cancer Patients for Herceptin Use |
| February 24, 2011 | Herceptin May Boost Long-Term Survival After Aggressive Breast Cancer |
| October 21, 2010 | Roche: FDA Approves Herceptin for Stomach Cancer |
| January 28, 2010 | Herceptin Again Proves Mettle Against Breast Cancer |
| December 14, 2009 | Novel Drug Combo Improves Breast Cancer Survival |
| December 12, 2009 | Chemo With Herceptin May Be Best for Some Breast Cancers |
| November 3, 2009 | Drug Could Help Treat Small HER2-Positive Breast Tumors |
| September 14, 2009 | Routine Testing Would Improve Herceptin Use in Breast Cancer |
